P-275 CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
Sundar Jagannath(Mount Sinai Hospital), Yi Lin(Sichuan Agricultural University), Deepu Madduri(Johnson & Johnson (United States)), Enrique Zudaire(Centro de Investigación del Cáncer), Mounzer Agha(Dana-Farber Cancer Institute), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Nikhil C. Munshi(Dana-Farber Cancer Institute), Lida Pacaud(Centro de Investigación del Cáncer), Jesús G. Berdeja(Tennessee Oncology), Abhinav Deol(Wayne State University), Elizabeth O’Donnell(Harvard University), Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), Myo Htut(City of Hope), Christopher delCorral, Tzu‐Min Yeh(Centro de Investigación del Cáncer), Thomas Martin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Carolyn C. Jackson(Centro de Investigación del Cáncer), Adam Cohen(UPMC Hillman Cancer Center), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 4
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k